-
0
Patient Assessment
- 0.1 Patient Demand
- 0.2 Anatomical location
-
0.3
Patient History
- 2.1 General patient history
- 2.2 Local history
-
0.4
Risk Assessment
- 3.1 Risk Assessment Overview
- 3.2 Age
- 3.3 Patient Compliance
- 3.4 Smoking
- 3.5 Drug Abuse
- 3.6 Recreational Drug and Alcohol Abuse
- 3.7 Condition of Natural Teeth
- 3.8 Parafunctions
- 3.9 Diabetes
- 3.10 Anticoagulants
- 3.11 Osteoporosis
- 3.12 Bisphosphonates
- 3.13 MRONJ
- 3.14 Steroids
- 3.15 Radiotherapy
- 3.16 Risk factors
-
1
Diagnostics
-
2
Treatment Options
-
2.1
Treatment planning
- 0.1 Non-implant based treatment options
- 0.2 Treatment planning conventional, model based, non-guided, semi-guided
- 0.3 Digital treatment planning
- 0.4 NobelClinician and digital workflow
- 0.5 Implant position considerations overview
- 0.6 Soft tissue condition and morphology
- 0.7 Site development, soft tissue management
- 0.8 Hard tissue and bone quality
- 0.9 Site development, hard tissue management
- 0.10 Time to function
- 0.11 Submerged vs non-submerged
- 0.12 Healed or fresh extraction socket
- 0.13 Screw-retained vs. cement-retained
- 0.14 Angulated Screw Channel system (ASC)
- 2.2 Treatment options esthetic zone
- 2.3 Treatment options posterior zone
- 2.4 Comprehensive treatment concepts
-
2.1
Treatment planning
-
3
Treatment Procedures
-
3.1
Treatment procedures general considerations
- 0.1 Anesthesia
- 0.2 peri-operative care
- 0.3 Flap- or flapless
- 0.4 Non-guided protocol
- 0.5 Semi-guided protocol
- 0.6 Guided protocol overview
- 0.7 Guided protocol NobelGuide
- 0.8 Parallel implant placement considerations
- 0.9 Tapered implant placement considerations
- 0.10 3D implant position
- 0.11 Implant insertion torque
- 0.12 Intra-operative complications
- 0.13 Impression procedures, digital impressions, intraoral scanning
- 3.2 Treatment procedures esthetic zone surgical
- 3.3 Treatment procedures esthetic zone prosthetic
- 3.4 Treatment procedures posterior zone surgical
- 3.5 Treatment procedures posterior zone prosthetic
-
3.1
Treatment procedures general considerations
-
4
Aftercare
Bisphosphonates
Key points
- Bisphosphonates (BP) maintain bone mass and stability and are used in treatment of bone diseases such as osteoporosis.
- BP therapy in osteoporosis patients is not a contra-indication for implant treatment.
- BP medication for bone cancers like multiple myeloma constitute a contra-indication for implant treatment.
Bisphosphonates - general
Bisphosphonates (BP) inhibit osteoclast activity and remain in the bone for a prolonged period. Bisphosphonates are the most commonly prescribed drugs to treat osteoporosis, bone fragility disorders, like Paget’s disease, osteogenesis imperfecta, fibrous dysplasia and bone cancers.
Side effects
In the oro-maxillo-facial region, when administered over a long period, bisphosphonates may predispose to ‘bisphosphonate-related osteonecrosis of the jaw’ (BRONJ). The mandible is affected twice as frequently as the maxilla.
Risk for implant treatment
A variety of studies indicate that implant placement, as such, does not predispose the patient with a history of bisphosphonate therapy to implant failure or to developing BRONJ. However, each individual patient should be evaluated for key factors such as delivery mode (IV or oral intake) and duration of bisphosphonate therapy and any antecedents of healing problems following osseous surgery. Patients who have a long duration of bisphosphonate therapy and a history of poor bone healing following surgery are not candidates for implant placement.
